The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Source: [NPR News](https://www.npr.org/2026/08/01/nx-s1-5897441/fda-mrna-moderna-flu-vaccine)